Active immunization toward the MAGE-A3 antigen in patients with metastatic melanoma: Four-year follow-up results from a randomized phase II study (EORTC16032-18031).

@article{Kruit2011ActiveIT,
  title={Active immunization toward the MAGE-A3 antigen in patients with metastatic melanoma: Four-year follow-up results from a randomized phase II study (EORTC16032-18031).},
  author={Willem H Kruit and Stefan Suciu and Brigitte Dr{\'e}no and Vanna Chiarion-Sileni and Laurent Mortier and Caroline Robert and Michele Maio and Fr{\'e}d{\'e}ric F. Lehmann and Vincent G Brichard and Alan Spatz and A. M. M. Eggermont and Ulrich Keilholz},
  journal={Journal of clinical oncology : official journal of the American Society of Clinical Oncology},
  year={2011},
  volume={29 15_suppl},
  pages={8535}
}
8535 Background: Active immunization towards MAGE-A3 tumor antigen is a potential new approach to treat cancer. Current data from pilot studies have shown that a strong and persistent immune response is obtained when an immunostimulant is added to recombinant MAGE-A3 protein. This open labeled, randomized Phase II trial ( NCT00086866 ) has been designed to… CONTINUE READING